Our results confirmed the reported data concerning the inability of Spry4wt protein to interfere with cell proliferation and migration of the osteosarcoma-derived U2OS cells, but additionally, the experiments show that a variation at position 177 (lysine to arginine) enables the Spry4 protein to function as an efficient inhibitor of these processes. Here, SPRY4 is linked to osteosarcoma.